Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma × Tenofovir × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hepatitis B 3 Carcinoma, Hepatocellular 3 Lymphoma, B-Cell 1 Lymphoma 1 Hepatitis B, Chronic 1

Interventions

Cyclophosphamide 50 Vincristine 48 Doxorubicin 45 Prednisone 38 Rituximab 37 Radiotherapy 31 Etoposide 29 Cytarabine 20 Filgrastim 18 Methotrexate 17 Bleomycin 17 Dexamethasone 14 VAP-cyclo protocol 11 Carmustine 11 Vinblastine 10 Prednisolone 10 Peripheral Blood Stem Cell Transplantation 10 Mitoxantrone 9 Mercaptopurine 9 Melphalan 9 Dacarbazine 8 Leucovorin 7 Lenalidomide 7 ibrutinib 6 Procarbazine 6 Ifosfamide 6 Granulocyte Colony-Stimulating Factor 6 Gemcitabine 6 Daunorubicin 6 Bendamustine Hydrochloride 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02186574 2019-12-12

Tenofovir to Prevent HBV Reactivation

University Health Network, Toronto

Phase 3 Unknown

Hepatitis B, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡